Gossamer Bio, Inc. (GOSS) Cash Flow Statement
Gossamer Bio, Inc. (GOSS) generated -$162.6M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$162.6M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GOSSGossamer Bio, Inc.Follow GOSS — free
—
Price chart with a free account
- Market cap
- 4.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -3.5 | -171.3 | -162.6 | |
| Capital expenditure | 0.0 | 0.1 | -0.0 | |
| Free cash flow | -3.5 | -171.3 | -162.6 | |
| Stock-based compensation | 20.6 | 10.6 | — |
USD millions · SEC XBRL
Gossamer Bio, Inc. — questions
- What is Gossamer Bio, Inc.'s operating cash flow?
- -$162.6M over the twelve months to 2026-06-30.
- How much does Gossamer Bio, Inc. spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Gossamer Bio, Inc.'s free cash flow?
- -$162.6M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Gossamer Bio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.